A Real Life, Non-interventional, Multicentre Study to Assess Resource Utilization and Quality of Life of Patients With Relapsing Forms of Multiple Sclerosis Treated With Dimethyl Fumarate in Greece - the FIDELITY Study
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms FIDELITY
- Sponsors Genesis Pharma
- 31 Jul 2018 Planned End Date changed from 23 Sep 2018 to 31 Mar 2020.
- 31 Jul 2018 Planned primary completion date changed from 23 Sep 2018 to 31 Mar 2020.
- 31 Jul 2018 Status changed from recruiting to active, no longer recruiting.